CiToxLAB North America Inc.

ADME is the evaluation of absorption, distribution, metabolism and excretion properties of compounds and their metabolites. We can help you develop ADME testing strategies spanning early stage development, preclinical toxicity and through your clinical trials.

The synergy within our group gives you a head start for competitive time-lines and efficient advice. You gain easy assess to our experts and we can evaluate your precise requirements and ensure you get the best ADME package at the best price.

With today’s computer technology, we can offer predictive modelling for your drug candidates. This cost-effective technique is principally applicable for :

Impurity assessment : Pharmaceuticals generally contain low levels of impurities, the genotoxicity of which can be evaluated by in silico modelling.

• A wide range of genotoxicity endpoints can be assessed in parallel.
  

Results are interpreted against available preclinical data and intended clinical application. To make sure you get the best and most competitive solution, you will receive all necessary information in a format that is user-friendly and relevant to regulatory authority submission.

Understanding mechanisms of action and predicting toxicity in drug candidates can help you define the most efficient testing strategy. Predictive toxicology screening can highlight areas where candidate molecules have potential issues at a very early stage, facilitating drug candidate selection for further pre-clinical development.

Predictive toxicology screening for structuring formal testing packages; some examples:

• Dermal screening for potential skin sensitisation and dermal irritation
  
• QSAR for genotoxicity assessment
  
• Toxicogenomics to assess potential hepatotoxicity
  

Our priority is accompanying you in your preclinical compound development, so we are always happy to advise you on drug candidate selection packages using our discovery and predictive toxicology services.

With today’s computer technology, we can offer predictive modelling for your drug candidates. This cost-effective technique is principally applicable for :

Drug candidate assessment : Based on the chemical structure and molecular substructure of tested compounds, each molecule is modelled by the computer-driven QSAR system.

• QSAR analysis helps to understand the potential molecular dynamics between compounds under development and other chemical structures.
  

Results are interpreted against available preclinical data and intended clinical application. To make sure you get the best and most competitive solution, you will receive all necessary information in a format that is user-friendly and relevant to regulatory authority submission.

ADME is the evaluation of absorption, distribution, metabolism and excretion properties of compounds and their metabolites. We can help you develop ADME testing strategies spanning early stage development, preclinical toxicity and through your clinical trials.

The synergy within our group gives you a head start for competitive time-lines and efficient advice. You gain easy assess to our experts and we can evaluate your precise requirements and ensure you get the best ADME package at the best price.

Including transgenic models –TgRas H2, p53 knockout, and TgAC